检索结果 - Jan Walewski
- Showing 1 - 20 results of 47
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY1... 由 Graham M. Mead, Sharon Barrans, Wendi Qian, Jan Walewski, John Radford, Max Wolf, Simon Clawson, Sally Stenning, Claire L. Yule, Andrew Jack
出版 2008Artigo -
6
Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study 由 Michael A. Rieger, Anders Österborg, Ruth Pettengell, Darrell White, Devinder Gill, Jan Walewski, Evelyn Kuhnt, Markus Loeffler, Michael Pfreundschuh, Anthony D. Ho
出版 2010Artigo -
7
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 由 Hervé Tilly, María Gomes da Silva, Umberto Vitolo, Andrew Jack, Michel Meignan, Armando López‐Guillermo, Jan Walewski, M. André, Peter Johnson, Michael Pfreundschuh, Marco Ladetto
出版 2015Artigo -
8
Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN971... 由 Peter Johnson, John Radford, Michael Cullen, Matthew R. Sydes, Jan Walewski, Andrew Jack, Kenneth MacLennan, Sally Stenning, Simon Clawson, Paul Smith, David Ryder, Barry W. Hancock
出版 2005Artigo -
9
Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase... 由 Pier Luigi Zinzani, Nuriet K. Khuageva, Huaqing Wang, Bernardo Garicochea, Jan Walewski, Achiel Van Hoof, Pierre Soubeyran, Dolores Caballero, Rena Buckstein, Dixie‐Lee Esseltine, Panteli Theocharous, Christopher Enny, Eugene Zhu, Yusri Elsayed, Bertrand Coiffier
出版 2012Artigo -
10
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse 由 Craig H. Moskowitz, Jan Walewski, Auayporn Nademanee, Tamás Masszi, Edward Agura, Jerzy Hołowiecki, Muneer H. Abidi, Andy I. Chen, Patrick J. Stiff, Simonetta Viviani, Veronika Bachanová, Anna Sureda, Teresa McClendon, Connie Lee, Julie Lisano, John Sweetenham
出版 2018Artigo -
11
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial 由 Anton Hagenbeek, Ole Gadeberg, Peter Johnson, Lars Møller Pedersen, Jan Walewski, Andrzej Hellmann, Brian K. Link, Tadeusz Robak, Marek Z. Wojtukiewicz, Michael Pfreundschuh, Michael Kneba, Andreas Engert, Pieter Sonneveld, Mimi Folden Flensburg, Jørgen Holm Petersen, Nedjad Losic, John Radford
出版 2008Artigo -
12
Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial 由 Pier Luigi Zinzani, Catherine Thiéblemont, В Я Мельниченко, Dzhelil Osmanov, Krimo Bouabdallah, Jan Walewski, Alejandro Majlis, Laura Fogliatto, M. D. Caballero Barrigón, Christian Bach, Zafer Gülbaş, Muhi̇t Özcan, Gilles Salles, Margaret A. Shipp, Arun Balakumaran, Sabine Chlosta, Arkendu Chatterjee, Philippe Armand
出版 2017Artigo -
13
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170 由 Pier Luigi Zinzani, Catherine Thiéblemont, В Я Мельниченко, Krimo Bouabdallah, Jan Walewski, Alejandro Majlis, Laura Fogliatto, Alejandro Martı́n, Beth Christian, Zafer Gülbaş, Muhi̇t Özcan, Guilherme Fleury Perini, Hervé Ghesquières, Margaret A. Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand
出版 2023Artigo -
14
Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial 由 Michael Northend, William Wilson, Kushani Ediriwickrema, Laura Clifton‐Hadley, Wendi Qian, Zaynab Rana, Tanya-Louise Martin, William Townsend, Moya Young, Fiona Miall, David Cunningham, Jan Walewski, Burhan Ferhanoğlu, Kim Linton, Amanda Johnston, John F. Seymour, David C. Linch, Kirit M. Ardeshna
出版 2025Artigo -
15
Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL 由 Christian H. Geisler, Mars B. van ’t Veer, Jesper Jurlander, Jan Walewski, Geir E. Tjønnfjord, Maija Itälä Remes, Eva Kimby, Tomáš Kozák, Aaron Polliack, Ka Lung Wu, Shulamiet Wittebol, Martine C. J. Abrahamse-Testroote, Jeanette K. Doorduijn, Wendimagegn Alemayehu, Marinus H. J. van Oers
出版 2014Artigo -
16
Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network 由 Chan Y. Cheah, Anupkumar George, Eva Giné, Annalisa Chiappella, Hanneke C. Kluin‐Nelemans, Wojciech Jurczak, Katarzyna Krawczyk, Heidi Móciková, Pavel Klener, D. Šálek, Jan Walewski, Michał Szymczyk, Lukáš Smolej, Rebecca Auer, David Ritchie, Luca Arcaini, Michael E. Williams, Martin Dreyling, John F. Seymour
出版 2013Artigo -
17
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial 由 Bertrand Coiffier, Evgenii A. Osmanov, Xiaonan Hong, Adriana Scheliga, Jiřı́ Mayer, Fritz Offner, Simon Rule, Adriana Teixeira, Jan Walewski, Sven de Vos, Michael Crump, Ofer Shpilberg, Dixie‐Lee Esseltine, Eugene Zhu, Christopher Enny, Panteli Theocharous, Helgi van de Velde, Yusri Elsayed, Pier Luigi Zinzani
出版 2011Artigo -
18
A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration 由 Grzegorz Rymkiewicz, Beata Grygalewicz, Magdalena Chechlińska, Katarzyna Błachnio, Zbigniew Bystydzieński, Joanna Romejko‐Jarosińska, Renata Woroniecka, Michalina Zajdel, Katarzyna Domańska‐Czyż, David Martin‐García, Ferran Nadeu, Paweł Swoboda, Jolanta Rygier, Barbara Pieńkowska‐Grela, Jan Konrad Siwicki, Monika Prochorec–Sobieszek, Itziar Salaverría, Reiner Siebert, Jan Walewski
出版 2018Artigo -
19
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy 由 David J. Straus, Graham P. Collins, Jan Walewski, Pier Luigi Zinzani, Andrew Grigg, Anna Sureda, Árpád Illés, Tae Min Kim, Sergey Alekseev, Lena Specht, Valéria Buccheri, Anas Younes, Joseph M. Connors, Andres Forero‐Torres, Keenan Fenton, Ashish Gautam, Indra Purevjal, Rachael Liu, Andrea Gallamini
出版 2020Artigo -
20
Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network 由 Eva Hoster, Wolfram Klapper, Olivier Hermine, Hanneke C. Kluin‐Nelemans, Jan Walewski, Achiel Van Hoof, Marek Trněný, Christian H. Geisler, Francesco Di Raimondo, Michał Szymczyk, Stephan Stilgenbauer, Catherine Thiéblemont, Michael Hallek, Roswitha Forstpointner, Christiane Pott, Vincent Ribrag, Jeanette K. Doorduijn, Wolfgang Hiddemann, Martin Dreyling, Michael Unterhalt
出版 2014Artigo
相关主题
Medicine
Internal medicine
Oncology
Lymphoma
Surgery
Gastroenterology
Mantle cell lymphoma
Rituximab
Chemotherapy
Immunology
Clinical endpoint
Follicular lymphoma
Brentuximab vedotin
Clinical trial
Diffuse large B-cell lymphoma
Leukemia
Transplantation
Adverse effect
Cancer
Chronic lymphocytic leukemia
Neutropenia
Refractory (planetary science)
Astrobiology
Confidence interval
Pathology
Physics
Biology
Cancer research
Cyclophosphamide
Hazard ratio